Download a copy of "Validation of simple prediction algorithms to consistently achieve CD3+ and postselection CD34+ targets with leukapheresis"
From Transfusion (2020)

Cellular therapies using engineered T cells, haploidentical transplants, and autologous gene therapy are increasing.

Specified CD3+ or high CD34+ doses are typically required for subsequent manufacturing, manipulation, or CD34+ selection.Simple, practical, and reliable lymphocyte and hematopoietic progenitor cell (HPC) collection algorithms accounting for subsequent CD34+ selection have not been published.

Fill out the form below to download Validation of simple prediction algorithms to consistently achieve CD3+ and postselection CD34+ targets with leukapheresis, a study co-authored by Dr. Patricia Shi, Medical Director & Head of Clinical Research in Sickle Cell Disease at Comprehensive Cell Solutions.

Get your copy of the study below.